Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
George Georgiou
University of Texas, Austin, Department: Engineering (All Types)
Should you be removed from our database? Contact us at [email protected]. Read more below.
GMA, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The covered individual holds equity interest in GMA, LLC. The Covered Individual consults sponsored research on intellectual property that has been assigned to GMA, LLC. The Covered Individual is co-founder, a member of board of directors, and holds equity interest in Aeglea, LLC. The Covered Individual is inventor of technology licensed to Aeglea, LLC through GMA, LLC.
Human-Enzyme Mediated, Systemic Depletion of Cystine for Cancer Treatment.
Major drawbacks to current treatments of Prostate cancer (PCa) are resistance to androgen ablation therapy and chemotherapy associated toxicities that severely compromise quality of life. The finding that PCa (and other cancer types) display an excessive requirement of the amino acid L-cysteine relative to non-malignant tissues has led to the development of a completely novel therapeutic approach to treat PCa that exploits this critical vulnerability by using an engineered human enzyme to deprive tumor cells of L-cysteine. Most if not all normal tissue can make L-cysteine from the essential amino acid L-Methionine, thus only tumors are highly impacted when L-cysteine is unavailable.
Filed on August 01, 2014.
Tell us what you know about George Georgiou's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
George Georgiou filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| George Georgiou | University of Texas, Austin | Conflict of Interest | Aeglea Biotherapeutics | >$600,000 |
| George Georgiou | University of Texas, Austin | Conflict of Interest | Aeglea Biotherapeutics | $0 - $4,999 |
| George Georgiou | University of Texas, Austin | Conflict of Interest | Aeglea, LLC. | Value cannot be readily determined |
| George Georgiou | University of Texas, Austin | Conflict of Interest | Aeglea, LLC. | Value cannot be readily determined |
| George Georgiou | University of Texas, Austin | Conflict of Interest | Orros Biotherapeutics, LLC | Value cannot be readily determined |
Other search results for: “George Georgiou”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| George Georgiou | University of Texas, Austin | Financial Disclosure | Aeglea Biotherapeutics, LLC |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.